Buprenorphine substitution ameliorates spontaneous withdrawal in fentanyl-dependent rat pups

Pediatric Research

Volumn 49, Issue 1, 2001, Pages 50-55

  Lohmann, A B ^a   Smith, F L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; FENTANYL; MORPHINE; NALOXONE;

ANIMAL EXPERIMENT; ARTICLE; ARTIFICIAL VENTILATION; CLIMBING; CONTROLLED STUDY; DRUG EFFICACY; EXTRACORPOREAL OXYGENATION; FEMALE; JUMPING; MALE; MASTICATION; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; TREMOR; WET DOG SHAKES; WITHDRAWAL SYNDROME;

EID: 0035201698     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-200101000-00013     Document Type: Article

References (49)

1. Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation
2. Changes in pharmacodynamic response to fentanyl in neonates during continuous infusion
3. Opioid withdrawal in neonates after continuous infusions of morphine or fentanyl during extracorporeal membrane oxygenation
4. Analgesia and sedation in neonatal intensive care using fentanyl by continuous infusion
5. Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation
6. Routine use of fentanyl infusions for pain and stress reduction in infants with respiratory distress syndrome
7. A comparison of fentanyl and morphine use in neonates
8. After-effects of morphine and fentanyl analgesia: A retrospective study
9. Fentanyl citrate
10. Opioid tolerance and dependance in infants and children
11. Fentanyl infusion and weaning in the pediatric intensive care unit: Toward science-based practice
12. Drug withdrawal symptoms in children after continuous infusion of fentanyl
13. Prospective study on the occurrence of withdrawal in critically ill children who receive fentanyl by continuous infusion
14. Assessment and management of opioid withdrawal in ill neonates
15. Neonatal abstinence syndrome
16. Neonatal abstinence syndrome
17. Neonatal abstinence syndrome: Assessment and management
18. The course of the heroin withdrawal syndrome in neonates treated with phenobarbital or chlorpromazine
19. Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration
20. Clonidine in neonatal narcotic abstinence syndrome
21. Methadone as treatment for iatrogenic narcotic dependency in pediatric intensive care patients
22. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts
23. A controlled trial of buprenorphine treatment for opioid dependence
24. Comparison of buprenorphine and methadone in the treatment of opioid dependence
25. Clinical pharmacology of buprenorphine: Ceiling effects at high doses
26. Characterization of neonatal rat fentanyl tolerance and dependence
27. Long-term alterations in opioid antinociception resulting from infant fentanyl tolerance and dependence
28. Ontogeny of mu opioid agonist antinociception in postnatal rats
29. Characterization of neonatal rat morphine tolerance and dependence
30. Some narcotic antagonists in the benzomorphan series
31. Buprenorphine antagonism of mu-opioids in the Rhesus monkey tail-withdrawal procedure
32. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method
33. Use of β-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands
34. Antinociceptive effect of buprenorphine in mu1-opioid receptor deficient CXBK mice
35. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions
36. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa-3 analgesia
37. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes
38. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4
39. Comparative analysis of buprenorphineand norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling
40. The interaction of buprenorphine with the opiate receptor: Lipophilicity as a determining factor in drug-receptor kinetics
41. Buprenorphine kinetics
42. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal
43. Alternate-day dosing during buprenorphine treatment of opioid dependence
44. Buprenorphine suppresses heroin use by heroin addicts
45. Buprenorphine
46. Effects of buprenorphine and methadone in methadone-maintained subjects
47. Late pulmonary sequelae of bronchopulmonary dysplasia
48. Evolution and natural history of chronic lung disease of prematurity
49. The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates